ATHE

Business Context and Reporting Period

Company: Prana Biotechnology Limited (Note: Request metadata listed "Alterity Therapeutics," but the filing text identifies the registrant as Prana Biotechnology Limited).

Reporting Period: Fiscal year ended June 30, 2009.

Business Overview: Prana is an Australian-based development-stage biotechnology company focused on discovering and developing therapeutic drugs for age-related degenerative diseases of the brain and eye, primarily Alzheimer's disease. The company's lead candidate is PBT2, a metal protein attenuating compound (MPAC). The company has no commercial product sales and relies on equity financing, grants, and interest income.

Key Financial Metrics (Year Ended June 30, 2009)

Note: All figures are in Australian Dollars (A$). The company reported no debt or interest-bearing liabilities as of June 30, 2009, as warrants issued in 2004 expired unexercised.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately 45% (A$6.0 million) compared to 2008. This improvement was driven primarily by a 62% reduction in R&D expenses and a 28% reduction in personnel expenses.
• R&D Expenses: Significant decrease from A$5.76 million to A$2.22 million. Management attributes this to the completion of the Phase IIa clinical trial for PBT2 in early 2008, the costs of which were largely incurred in the prior year.
• Personnel Expenses: Decreased by A$1.52 million, largely due to lower equity-based compensation expenses (A$1.31 million in 2009 vs. A$2.24 million in 2008).
• Intellectual Property Expenses: Increased by 136% (A$0.64 million) due to the maturation of international patent applications into national phase filings and increased legal fees for potential licensing.
• Financial Liabilities: The company recorded a gain of A$772,430 on the fair value of financial liabilities (warrants) in 2009, compared to a loss of A$451,429 in 2008. The warrants expired unexercised in June 2009, eliminating this liability.
• Cash Position: Cash and cash equivalents declined by approximately 62% (A$6.9 million) due to operating cash outflows, despite the reduction in net loss.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity and Capital Resources: As of June 30, 2009, cash was A$4.3 million. Management believes this, combined with proceeds from a subsequent private placement (see below), is sufficient for operations for at least 12 months. However, the company anticipates requiring substantial additional funding for future clinical trials (Phase IIb) and regulatory approvals.
• Subsequent Financing: On September 8, 2009, the company entered into a private placement agreement to raise A$6.0 million (approx. A$5.7 million net) by issuing 30 million ordinary shares. This was intended to fund R&D and working capital.
• Outlook: The company plans to direct future R&D toward Phase II studies of PBT2 for Alzheimer's and Huntington's disease, as well as investigating lead candidates for Parkinson's disease and brain cancer.
• Risks:
  • Funding Risk: The company has a history of operating losses and requires significant capital to continue. Failure to secure funding could force a curtailment of operations.
  • Regulatory Risk: Success depends on obtaining regulatory approvals (FDA, TGA, etc.) for PBT2, which is not guaranteed.
  • PFIC Status: The company believes it qualifies as a Passive Foreign Investment Company (PFIC) for U.S. tax purposes, which may subject U.S. investors to adverse tax consequences.
  • Manufacturing: The company relies on sole manufacturers for its lead compound PBT2, creating supply chain risks.
• Unusual Items: The gain on fair value of financial liabilities (A$772,430) is a non-cash item resulting from the revaluation of warrants prior to their expiration.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the A$4.3 million cash balance plus the A$6.0 million subsequent private placement to fund the planned Phase IIb trials and ongoing operations.
• PFIC Status: Confirm the tax implications for U.S. investors given the company's classification as a Passive Foreign Investment Company.
• Clinical Trial Progress: Monitor the timeline and results of the planned Phase IIb trials for PBT2 in Alzheimer's and Huntington's disease.
• Patent Portfolio: Review the status of the key "8-Hydroxyquinoline derivatives" patent granted in Europe and pending in the U.S., which protects the PBT2 compound.
• Related Party Transactions: Note the significant equity holdings and option grants to directors and key management personnel, which may impact future dilution.